Endocrine therapy is currently the cornerstone of treatment for advanced hormone receptor–positive (HR+) breast cancer in both pre- and postmenopausal patients. However, not all advanced HR+ breast cancers respond to first-line endocrine therapy, and those that do respond eventually relapse. Agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, have been approved by the US Food & Drug Administration (FDA) for the treatment of HR+/human epidermal growth factor receptor 2–negative (HER2−) advanced/metastatic breast cancer. Now, CDK 4/6 inhibitors are being investigated for the treatment of early stage HR+, HER2- breast cancer.
This web-based, on-demand, activity will feature interprofessional perspectives and expert insights on the latest emerging evidence for CDK 4/6 inhibitors in the adjuvant setting for early breast cancer. The faculty panel will also provide their perspectives and best practice recommendations for improving adherence and side effect management. Case-based discussion will provide practical approaches for integrating CDK 4/6 inhibitors into real-world clinical practice for the treatment of early stage HR+, HER2- breast cancer.